Učitavanje...
CIP2A Constrains Th17 Differentiation by Modulating STAT3 Signaling
Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) is an oncogene and a potential cancer therapy target protein. Accordingly, a better understanding of the physiological function of CIP2A, especially in the context of immune cells, is a prerequisite for its exploitation in cancer therapy. Here, w...
Spremljeno u:
| Izdano u: | iScience |
|---|---|
| Glavni autori: | , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7068643/ https://ncbi.nlm.nih.gov/pubmed/32171124 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2020.100947 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|